anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Persistent chest pain (PCP) following acute COVID-19 infection is a commonly reported symptom with an unclear etiology, making its management challenging. This scoping review aims to address the knowledge gap surrounding the characteristics of PCP following COVID-19, its causes, and potential treatments. This is a scoping review of 64 studies, including observational (prospective, retrospective, cross-sectional, case series, and case-control) and one quasi-experimental study, from databases including Embase, PubMed/MEDLINE, Cochrane CENTRAL, Google Scholar, Cochrane Database of Systematic Reviews, and Scopus. Studies on patients with PCP following mild, moderate, and severe COVID-19 infection were included. Studies with patients of any age, with chest pain that persisted following acute COVID-19 disease, irrespective of etiology or duration were included. A total of 35 studies reported PCP symptoms following COVID-19 (0.24%-76.6%) at an average follow-up of 3 months or longer, 12 studies at 1-3 months and 17 studies at less than 1-month follow-up or not specified. PCP was common following mild-severe COVID-19 infection, and etiology was mostly not reported. Fourteen studies proposed potential etiologies including endothelial dysfunction, cardiac ischemia, vasospasm, myocarditis, cardiac arrhythmia, pneumonia, pulmonary embolism, postural tachycardia syndrome, or noted cardiac MRI (cMRI) changes. Evaluation methods included common cardiopulmonary tests, as well as less common tests such as flow-mediated dilatation, cMRI, single-photon emission computed tomography myocardial perfusion imaging, and cardiopulmonary exercise testing. Only one study reported a specific treatment (sulodexide). PCP is a prevalent symptom following COVID-19 infection, with various proposed etiologies. Further research is needed to establish a better understanding of the causes and to develop targeted treatments for PCP following COVID-19.
1,220,468. α-Glyceryl esters. SCHERICO Ltd. 5 April, 1968 [10 April, 1967 (2)], No. 16477/68. Heading C2C. Novel compounds of formula I and cyclic acetals and ketals and salts thereof wherein A is N or CH, R is H or CH 3 , R<SP>1</SP> is alkyl, alkoxy, halogen CF 3  or NO 2 , R<SP>2</SP> and R, are each H, NO 2 , CF 3 , halogen or alkyl are prepared by condensation by known methods of a compound of formula Y.CH 2 X<SP>1</SP> with a compound of formula wherein X<SP>1</SP> is an α,#-dihydroxyethyl group or a cyclic acetal or ketal thereof or is a vinyl or epoxyethyl group and Y and Z are groups capable of condensing during the reaction to leave a bridge of formula between the groups -CH 2 X<SP>1</SP> and that of formula and, where X<SP>1</SP> is vinyl or epoxyethyl, converting the product by known methods of oxidation and/or hydrolysis to a #,γ-dihydroxypropyl ester. The preferred exemplified method involves transesteriflcation of a compound of Formula VI wherein B is an electron withdrawing group, e.g. cyano, carbamoyl, acyl or carbethoxy, with an alcohol of formula HO.CHOH.CH 2 OH or a cyclic ketal thereof, optionally followed by splitting off the ketal group. Intermediates of Formula VI above wherein B is H, cyano, carbamoyl, acetyl, benzoyl, carbethoxy and vinyl are prepared either by esterification of the free acid or transesterification of the methyl ester with the appropriate alcohol HOCH 2 B or in the case of the compound B=carbamoyl by hydrolysis of the compound B=CN. Anilinonicotinic acids and their esters used to prepare intermediates of Formula VI above wherein A is N are prepared either by reaction of an appropriate 2-chloronicotinic acid or ester and an appropriately substituted aniline. Pharmaceutical compositions having antiinflammatory antipyretic and analgesic action in conventional forms for oral, rectal, topical or transcutaneous administration comprise an above novel compound and pharmaceutical carriers or excipients.
Herpoxin, herpes virus inhibitor consists of two proteins isolated from snake venom of Naja n. kaouthia, which separately and together inhibit the replication of herpes simplex viruses type 1 and type 2 in cell cultures. Herpoxin is characterized as a purified component of snake venom, of the phospholipase A 2  (PhA2) enzyme family, which inhibits production of the typical cytopathogenic effects (CPE) produced by herpes viruses type 1 and type 2. Herpoxin consists of two peptides Herp-A and Herp-B having molecular weights 14,000 and 15,000 daltons, respectively, as revealed by gel electrophoresis. The partial sequence for the first fifteen N-terminal amino acids of both Herp-A and Herp-B is: Asn-Leu-Tyr-Gln-Phe-Lys-Asn-Met-Ile-Gln-Cys-Thr-Val-Pro-Asn, which will be referred to as SEQ ID No: 1. The known partial sequences for Herp-A and Herp-B proteins are identical and are typical of phospholipases. However, Herp-A and Herp-B are antigenicaily distinct. Herpoxin is claimed for its method of purification and as a treatment for herpes virus type 1 and type 2 induced oral and genital lesions and other infections. Herpoxin is further claimed as a therapeutic agent for non invasive topical application to treat other viral infections such as: herpes zoster, Kaposi sarcoma in AIDS patents, eczema, etc. It is also an object of this invention to provide Herpoxin as a composition for the treatment of skin infections induced by other microbial agents.
The lack of adherence to Goal-Directed Medical Therapy (GDMT) is a major problem in modern HF care. Despite advances in therapies for those with HF along with well-articulated goals for achieving guideline-directed medical therapy (GDMT) for affected individuals, the treatment of persons with HF lags behind current recommended guideline approaches, with 30% of ambulatory patients with HFrEF not being prescribed angiotensin receptor/neprilysin inhibitors (ARNI), angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB), or evidence based beta blockers (eBBB) and the majority not receiving target doses of these medications despite lack of medical contraindications. The reasons for gaps in care include hesitancy to change medical programs in ostensibly stable patients, concerns about risk of drug intolerances, worries about drug costs, as well as uncertainty about benefits. Additionally, complexity of medical therapy, rapid evolution in the currently recommended therapeutic options, and challenges in care coordination also result in missed treatment opportunities. Given that most individuals with HF are cared for by specialists other than those trained in advanced HF therapies, this intersection of increasing complexity of care results in substantial gaps in care. The proposed research is to study impact of the GDMT clinic for patients across the spectrum of HF.
If taking part in this study, the patient will either get docetaxel, or carboplatin in addition to docetaxel. In both cases, the cancer will be monitored by CT scans and bone scans every 9 weeks, and blood tests every 3 weeks. Study treatments, scans, and tests will continue until the disease gets worse.

After finishing study treatment, even if treatment is stopped before the disease gets worse, the study doctor will continue to follow patients condition, watch for side effects and keep track of the health of the patient. If treatment is stopped before the disease got worse, patients will be asked to continue getting CT scans and bone scans every 9 weeks, and blood tests every 3 weeks, until the disease worsens. If the disease gets worse while receiving treatment, or after treatment is stopped, the patient will be contacted by phone every 3 months for the rest of their life to monitor their status. Patients may be seen more often if the study doctor thinks it is necessary.
High-level athletic performances may be a proxy for the trajectory of optimal function of human biology with advanced aging and the differences between males and females. Males are faster, stronger, and more powerful than females and these physical attributes decline dramatically with advanced aging for both sexes. Experimental mechanistic studies determine the physiological mechanisms for these sex and age differences in human physical performance. The assumption however, that real-world performances solely reflect the biological and physiological differences between the sexes and with advanced aging, even among elite athletes, is not complete. This review presents evidence that an integrated approach encompassing analysis of real-world data and experimental mechanistic studies is necessary to determine the biological and sociocultural factors attributed to the limits of performance with aging and between males and females. First, experimental studies are presented that focus on the sex and age differences in performance fatigability that determine the physiological mechanisms of absolute and relative exercise performance. Second, analysis of current and historical real-world data including world records, and performances of elite, collegiate, and competitive age-group athletes are highlighted. These data illustrate that the upper limits of physical performance that have changed historically, and other factors such as sociocultural influences, explain the widening of the sex and age gaps in human performance observed in real-world data even in present-day performances. These approaches have broader significance when applied to understanding the impact of the historically low representation of females and minority groups in biomedical research on health outcomes.
This present disclosure discloses a bioadhesive boric acid formulation and its use and preparation method. Specifically, a preferred vaginal bioadhesive boric acid formulation mainly comprises of: methylparaben, propylparaben, potassium sorbate, chitosan, glycerin, carbopol 974, polycarbophil, boric acid, and purified water. The vaginal boric acid preparation are capable of retaining and releasing boric acid in the vagina. It is proved experimentally that boric acid acts as an antibacterial component of this gel and can be maintained at a relatively high concentration in vaginal fluid. Further, it is demonstrated that the vaginal bioadhesive boric acid formulation has a dynamic viscosity >100000 cps, pH value of 2-5, good moisture retention capability. The formulation is non-allergenic, non-vaginal irritation, and capable of inhibiting bacteria and fungi.
FIELD: medicine, pharmacy, pharmaceutical industry. SUBSTANCE: invention concerns medicinal forms comprising interferon preparations. Invention proposes gel containing interferon and vitamin E and including additionally methionine, benzoic acid, citric acid, ethyl alcohol, glycerol, human serum albumin, sodium carboxymethylcellulose, sodium tetraborate and water. Gel exhibits the more broad spectrum of therapeutic using, more degree of an antiviral activity as compared with that in prototype in equal doses of interferon. Preparation does not induce adverse effects. EFFECT: decreased cost, improved facility in using, enhanced activity and properties. 3 tbl, 2 ex
PURPOSE: An antifibrotic agent of the liver containing an extract of Platycodi Radix of 20 years or more as an effective ingredient is provided. The extract of 20 year old Platycodi Radix has better pharmacological action and physiological activity than that of 2 to 4 year old one and is effective in treatment and prevention of liver diseases such as cirrhosis, liver fibrosis or the like. CONSTITUTION: An antifibrotic agent of the liver contains an extract of 20 year old Platycodi Radix. The Platycodi Radix extract is a water extract or an organic solvent extract. In the extraction process, Platycodi Radix powder is added about 5 to 10 times with water and extracted two times for 4 to 6hr at 90 to 100deg.C. Platycodi Radix powder is added about 3 times with an organic solvent, extracted two times at room temperature and then concentrated under reduced pressure. The organic solvent is methanol or ethanol. The extract has no toxicity to a human body and exhibits lower adverse effects than conventional chemotherapeutic agents.
FIELD: cosmetics. SUBSTANCE: invention relates to the cosmetic photoresistant composition used for protection of skin and/or hair against ultraviolet radiation. Composition comprises in a carrier a derivative of dibenzoylmethane as a filter that shows effectiveness in UV-A region and polysaccharide alkyl ether. The latter is formed by links containing different ozidium cycles being each link has hydroxyl-group substituted with saturated hydrocarbon alkyl chain and used as a stabilizing agent in this composition. Invention relates to also a method of photostabilization of the composition and a method of skin and hair protection against effect of ultraviolet radiation. EFFECT: photostability of the composition. 44 cl, 2 tbl, 2 ex
The present invention relates to a medicine for treating gynecological diseases, which uses bupleurum root, angelica, cyperus tuber, corydalis tuber, laminaria, seaweed, dangshen, etc. as raw materials. The raw materials are uniformly mixed to be made into capsules after being pulverized. The medicine of the present invention treats both manifestation and the root sources of diseases, and has rapid medical effect. The medicine can be used for treating various gynecological symptoms, such as abdominal lump glomus, menoxenia, dysmenorrhea, amenorrhea, lump in breast, etc. caused by female qi stagnation, blood stasis, cold-damp coagulation, phlegm stagnation, dyspepsia, etc., and can also be used for treating colic.
PURPOSE: To enable pesticides to be removed from ginseng roots without damage to its agonist by adjusting the moist content of the ginseng roots to a specific level before the extraction treatment thereof with compressed carbon dioxide. CONSTITUTION: Before the extraction treatment of ginseng roots, the moist content is adjusted to 14 to 65wt.% and the roots are extracted with compressed carbon dioxide thereby removing the pesticide. For example, after drying, the ginseng roots of about 8-10wt.% natural water content is increased to 14-25wt.%, advantageously by crashing the roots before the extraction and advantageously by adding water. For example, when the roots in the perfect form is used, water can be added by 4-12wt.% based on the starting weight of the ginseng roots. In addition, the harvested, but undried roots can be directly extracted, too. In this case, the addition of water is unnecessary.
PCT No. PCT/GB97/02029 Sec. 371 Date Feb. 12, 1999 Sec. 102(e) Date Feb. 12, 1999 PCT Filed Jul. 25, 1997 PCT Pub. No. WO98/06705 PCT Pub. Date Feb. 19, 1998This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.
The present invention relates to Chinese medicine umbilicus sticking power for treating child anorexia and dietary bias, particularly to umbilicus sticking powder for treating child anorexia, which is prepared from ginseng, common yan rhizomes, largehead atractylodes rhizomes, hyacinth beans, coix seeds, parched hawthorn fruit, stir-baked medicated leaven, stir-baked corium stomachium galli, colored malt, stir-baked semen raphani, terminal chebula, dried ginger, almond, prepared liauorice roots, dried tangerine peel, dendrobium, polygonatum, etc. When used, the umbilicus sticking powder is filled in an umbilicus to be covered by absorbent cotton and preforated rubberized fabric, and seven days form a course of treatment. The umbilicus sticking powder can strengthen the spleen and stomach, relieve dyspepsia, and benefit qi for promoting production of fluid, and thus, the present invention has conspicuous curative effects on child anorexia and dietary bias. The umbilicus sticking powder has 50 examples of clinical application and two course of treatment for whole treatment. The present invention has the effects that 36 cured persons with the proportion of 62% return to normal eating, have no food selection, drink water normally and persist for more than half year; 11 improved persons with the proportion of 22% return to normal eating, have dinners with drinking water and select food; three persons with the proportion of 6% can eat more food after treatment; no toxic and side effects occur. Thus, the umbilicus sticking powder has conspicuous curative effects on child anorexia and dietary bias.
FIELD: food industry.SUBSTANCE: group of inventions relates to a digestive enzyme composition, a method for producing such a composition, and a method for treating a pediatric or adult patient. Digestive enzyme composition contains a pancrelipase enteric-coated product in a therapeutically effective amount, an administrable nutrient medium, a pharmaceutically acceptable low viscosity oil ingredient for enteral administration. Said low viscosity oil ingredient is selected from a group consisting of vegetable oils, synthetic oils, fatty acids or mixtures thereof, and said nutrient medium is a nutrient mixture or soft food product. Pancrelipase product is an enteric-coated pancrelipase product, in a therapeutically effective amount of approximately 10,000 lipase ME (international units) Pharm. USA (US Pharmacopeia) or more, administrable nutrient medium is present in an amount of about 2 ml to about 15 ml for each from about 5,000 to about 20,000 lipase ME Farm. US pancrelipase product, the low viscosity oil ingredient is present in an amount from about 5 % to about 25 % v/v of the administrable nutrient medium, and a G probe used for enteral administration has an internal diameter of at least about 18 Fr (French scale units; 6 mm). Method is also disclosed for preparing a digestive enzyme composition, comprising mixing an enteric-coated pancrelipase product, an administrable nutrient medium, a pharmaceutically acceptable low viscosity oil ingredient. Method of treating a pediatric or adult patient in need of said digestive enzyme composition, including enteral administration to a patient of said digestive enzyme composition, is also provided.EFFECT: group of inventions provides effective enteral administration of high dosages of large-size digestive enzyme particles without damaging the active ingredient.15 cl, 7 tbl, 5 ex
Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase. Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
Vocal cord paralysis is a common condition that significantly impairs laryngeal function and can even be life-threatening. Over nearly a century, researchers have conducted extensive animal and clinical studies to achieve accurate diagnosis and restore laryngeal function, making significant progress. Approaches have evolved from mechanically narrowing the glottis to restore phonation, to enlarging the glottis to relieve breathing difficulties, and ultimately to the development of surgical techniques aimed at restoring vocal cord mobility, significantly advancing the field. The publication of expert consensus guidelines on the diagnosis and treatment of vocal cord paralysis has standardized the principles and technical standards for managing this condition. However, a vast amount of related knowledge-including the disease's pathogenesis, diagnostic criteria, surgical principles, and techniques-still requires broader dissemination and further refinement. Advancing this knowledge will guide clinical practice and further enhance the diagnosis and treatment of this condition in China.
Background: Cytokine release syndrome, also termed "cytokine storm," is the leading cause of morbidity and mortality among patients with various conditions such as sepsis. While cytokine storm is associated with multiple organ damage, acute cardiac and renal injury represents a hallmark of cytokine storm. Since recent reports have suggested that cannabidiol (CBD) may assist in the treatment of inflammatory diseases, our objective was to examine the effect of CBD on cytokine storm-induced cardiac and renal injury using the lipopolysaccharide (LPS)-induced sepsis mouse model. Materials and Methods: At 8 weeks of age, mice were randomly assigned to receive CBD (15 mg/kg) or vehicle one hour before a single injection of either phosphate-buffered saline or LPS (10 mg/kg) for an additional 24 h. Results: Our results show that CBD improves cardiac function and reduces renal injury in a mouse model of cytokine storm. Moreover, our data indicate that CBD significantly reduces systemic and renal inflammation to contribute to the improvements observed in a cytokine storm-model of cardiac and renal injury. Conclusions: Overall, the findings of this study suggest that CBD could be repurposed to reduce morbidity in patients with cytokine storm particularly in severe infections such as sepsis.
The invention relates to an autologous dentritic cellular genetically-modified vaccine acting against cancer compact tumors of the human hepatocellular carcinoma, which vaccine is composed of activated genetically-modified and -regulated autologous dentritic cells as well as of genetically-modified premature dentritic cells or combination of them. The present invention comprises genetically-regulated mature and/or immature dentritic cells where the genetic induction has been effected outside the body with use of the human clone of the oncogene micoRNA Mir-216a/217 with the aim to augment the antigenic action against their cytotoxic T lemphocytes via hyper-expression of the antigenic receptors of the human hepatocellular carcinoma. The activation of these genetically-regulated cells of the human immune system is carried out by their fusion with separated cancer cells of the same patient, which cancer cells are derived from extraction of the cancer compact tumour-hepatocellular carcinoma of the same patient. These cells are genetically modified with human oncogenes microRNA Mir-216a/217 with the aim to increase the expression of TGF-β and PI3K/Akt of human oncogenes by, simultaneously, suspending the expression of onco-suppressor genes PTEN and SMAD of the patient wherefrom the compact tumour is derived. This leads to the deployment outside the body of clones of cancer-like dentritic antigen-presenting cells for the more efficient targeting and destruction of cancer cells in patients with hepatocellular cancer. The invention relates to the composition of a pharmaceutical preparation on a uniform acceptable compatible vector of the present autologous dentritic genetically-modified vaccine for the vaccination of patients suffering, more precisely, from hepatocellular cancer.